Efficacy and safety of fruquintinib plus investigator's choice of chemotherapy as second-line therapy in metastatic colorectal cancer: Updated results of a multi-center, single-arm, phase 2 trial

被引：0
|
作者：
Zhao, Wensi
Li, Jun
Li, Liping
Huang, Junping
Gong, Wei
Yu, Xiongjie
Le, Kefa
He, Linli
Han, Qi
Wang, Songlin
Tang, Ze
Li, Wenbin
Hua, Xianliang
Chen, Yongshun
机构：
[1] Wuhan Univ, Renmin Hosp, Wuhan, Peoples R China
[2] Cent Hosp Xiao Gan, Dept Oncol, Xiaogan, Peoples R China
[3] Xiantao First Peoples Hosp, Xiantao, Peoples R China
[4] Jianghan Oilfield Gen Hosp, Qianjiang, Peoples R China
[5] Hubei Univ Art & Sci, Dept Oncol, Xiang Yang Cent Hosp, Xiangyang, Peoples R China
[6] Peoples Hosp Shiyan, Shiyan, Peoples R China
[7] Peoples Hosp Yangxin, Dept Oncol, Yangxin, Peoples R China
[8] First Peoples Hosp Tianmen City, Hubei Technol Coll, Dept Abdominal & Pelv Med Oncol, Affiliated Hosp, Tianmen, Peoples R China
[9] Xianning Cent Hosp, Xianning, Peoples R China
[10] Zhongxiang Peoples Hosp, Zhongxiang, Peoples R China
[11] Huangshi Cent Hosp, Dept Oncol, Huangshi, Hubei, Peoples R China
[12] Qianjiang Cent Hosp, Dept Oncol, Qianjiang, Peoples R China
[13] Wuhan Univ, Dept Clin Oncol, Renmin Hosp, Wuhan, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
基金：
中国国家自然科学基金;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3571
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Efficacy and safety of apatinib as second or later-line therapy in extensive-stage small cell lung cancer: a prospective, exploratory, single-arm, multi-center clinical trial
    Liu, Quan
    Xu, Juan-Ying
    Xu, Ye-Hong
    Chen, Meng
    Deng, Li-Chun
    Wu, Jian-Ping
    Zhou, Tong
    Zhang, Li-Qin
    Tan, Jie
    Pu, Xing-Xiang
    Shang, Yu-Long
    Hua, Jun
    Li, Yuan-Qin
    Cai, Wei
    Gu, Yu-Lan
    Peng, Xing-Chen
    Chan, Po-Chung
    Jabbour, Salma K.
    Nam, Hae-Seong
    Hua, Dong
    TRANSLATIONAL LUNG CANCER RESEARCH, 2022, 11 (05) : 832 - +
  • [22] Sintilimab plus anlotinib as second-line therapy for metastatic or recurrent gallbladder carcinoma (GBC): A single-arm, phase II study
    Cheng, Q.
    Jiang, X.
    ANNALS OF ONCOLOGY, 2022, 33 : S1468 - S1469
  • [23] Surufatinib plus doublet (FOLFOX/FOLFIRI) or triplet (FOLFOXIRI) chemotherapy as second-line therapy in metastatic colorectal cancer (mCRC): Updated results of a randomized, open-label, phase II trial
    Su, L.
    Lin, P.
    Huang, F.
    Ye, Z.
    Li, H.
    Zhuo, C.
    Wei, S.
    Yu, S.
    Li, J.
    Zheng, S.
    Hong, Y.
    Zheng, L.
    Zhao, S.
    Lin, R.
    ANNALS OF ONCOLOGY, 2024, 35 : S20 - S20
  • [24] Is gemcitabine plus vinorelbine active in second-line chemotherapy of metastatic breast cancer? A single-center phase 2 study
    Rossi, E
    Perrone, F
    Labonia, V
    Landi, G
    Nuzzo, F
    Amabile, G
    Gridelli, C
    Di Maio, M
    D'Aiuto, G
    de Matteis, A
    ONCOLOGY, 2003, 64 (04) : 479 - 480
  • [25] Efficacy and safety of second-line therapy by S-1 combined with sintilimab and anlotinib in pancreatic cancer patients with liver metastasis: a single-arm, phase II clinical trial
    Qiu, Xin
    Lu, Changchang
    Sha, Huizi
    Zhu, Yahui
    Kong, Weiwei
    Tong, Fan
    Wang, Qiaoli
    Meng, Fanyan
    Liu, Baorui
    Du, Juan
    FRONTIERS IN IMMUNOLOGY, 2024, 15
  • [26] Preliminary results of bevacizumab plus raltitrexed-based chemotherapy as second-line therapy in patients with metastatic colorectal cancer (mCRC): A multicenter phase II trial
    Li, S.
    Zhu, L.
    Zhu, C.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S723 - S723
  • [27] Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
    Chen, Yajie
    Wang, Kun
    Zhang Zhiyuan
    Zhang, Hui
    Yang, Wang
    Wu, Ruiyan
    Zhou, Menglong
    Zhang, Zhen
    Xia, Fan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [28] Efficacy and safety of anlotinib plus penpulimab as second-line treatment for small cell lung cancer: A multicenter, open-label, single-arm phase II trial
    Zhang, Changgong
    Chen, Jianhua
    Wu, Huijuan
    Wang, Jun
    Gao, Liying
    Zhao, Jun
    Sun, Yan
    Jia, Zhongyao
    Mu, Xinlin
    Bai, Chunmei
    Wang, Rui
    Wu, Kailiang
    Liu, Qiang
    Shi, Yuankai
    CANCER PATHOGENESIS AND THERAPY, 2024, 2 (04): : 268 - 275
  • [29] Stereotactic Ablative Radiotherapy Combined with Fruquintinib and Tislelizumab in Metastatic Colorectal Cancer: Updated Findings from a Single-Arm, Prospective Phase II Trial (RIFLE)
    Chen, Y.
    Wang, K.
    Zhang, Z.
    Zhang, H.
    Yang, W.
    Wu, R.
    Zhou, M.
    Zhang, Z.
    Xia, F.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (02): : E432 - E433
  • [30] Stereotactic ablative radiotherapy combined with fruquintinib and tislelizumab in metastatic colorectal cancer: Updated findings from a single-arm, prospective phase II trial (RIFLE)
    Chen, Y.
    Wang, K.
    Zhang, Z.
    Zhang, H.
    Yang, W.
    Wu, R.
    Zhou, M.
    Zhang, Z.
    Xia, F.
    ANNALS OF ONCOLOGY, 2024, 35 : S449 - S449
12345